Delcath
ApprovedDelcath is dedicated to revolutionizing the treatment of cancer patients with the newest liver directed treatment for metastatic ocular melanoma.
Founded
1988
Focus
Drug DeliverySmall Molecules
About
Delcath is dedicated to revolutionizing the treatment of cancer patients with the newest liver directed treatment for metastatic ocular melanoma.
Funding History
2Total raised: $35M
Debt$10MUndisclosedMay 15, 2022
PIPE$25MUndisclosedAug 15, 2021
Company Info
TypePrivate
Founded1988
LocationNew York, United States
StageApproved
Contact
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile